1. Serum Epidermal Growth Factor-like domain 7 Serves as a Novel Diagnostic Marker for Early Hepatocellular Carcinoma
- Author
-
Guo-Dong Chen, Meng-Yuan Yang, Hao Yang, Feng Fang, Lian-Yue Yang, Fan Wu, and Jing-Fan Zhang
- Subjects
Adult ,Male ,EGF Family of Proteins ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,Chronic liver disease ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,Biomarkers, Tumor ,Genetics ,medicine ,Humans ,Early Hepatocellular Carcinoma ,Eepidermal growth factor-like domain 7 ,neoplasms ,RC254-282 ,Aged ,Serum marker ,Receiver operating characteristic ,medicine.diagnostic_test ,business.industry ,Research ,Calcium-Binding Proteins ,Liver Neoplasms ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Middle Aged ,Early diagnosis ,medicine.disease ,digestive system diseases ,Oncology ,Alpha-fetoprotein ,030220 oncology & carcinogenesis ,Immunoassay ,Cohort ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Background Epidermal growth factor-like domain 7 (Egfl7), a recently identified secreted protein, was significantly increased in patients with HCC by our previous studies. However, its efficacy in the diagnosis of early HCC remains unknown. In this study, we therefore evaluate the efficacy of serum Egfl7 for early HCC diagnosis and compare it with alpha-fetoprotein (AFP). Methods Serum Egfl7 levels in testing cohort (1081 participants) and validation cohort (476 participants) were measured by a sandwich enzyme-linked immunoassay (ELISA). The cut-off value of Egfl7 was determined by Youden’s index and the efficacies of Egfl7 and AFP in diagnosing early HCC were estimated by receiver operating characteristic (ROC). Results Serum Egfl7 was significantly elevated in patients with early HCC than all non-HCC controls in whatever Testing Cohort or Validation Cohort. In the Testing Cohort, ROC curves showed the optimum cut-off value of Egfl7 was 2610 ng/mL and Egfl7 showed a significantly higher sensitivity than AFP in discriminating early HCC from healthy individuals (77.4% vs. 65.3%, P = 0.0013) but the area under ROC (AUROC) and accuracy of Egfl7 and AFP were similar (0.860 vs. 0.868, P = 0.704; 80.2% vs. 83.8%, P = 0.184). In distinguishing patients with early HCC from patients with chronic liver disease (CLD), the AUROC, sensitivity, specificity and accuracy of Egfl7 were 0.800, 75.2, 71.7 and 73.5%, which were all significantly higher than AFP (0.675, 61.8, 62.0 and 61.9% in order). Egfl7 also showed a significant higher sensitivity and accuracy than AFP (76.6% vs. 64.0%, P = 0.0031; 79.9% vs. 66.1%, P Conclusion Egfl7 is a valuable serum marker in the diagnosis of early HCC and could complement the efficacy of AFP, especially in distinguishing early HCC from CLD and identifying patients with AFP-negative early HCC.
- Published
- 2020
- Full Text
- View/download PDF